Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L HeerspinkBergur V StefánssonRicardo Correa-RotterGlenn M ChertowTom GreeneFan-Fan HouJohannes F E MannJohn Joseph Valentine McMurrayMagnus LindbergEllen BurgessC David SjöströmRoberto D TotoAnna-Maria LangkildeDavid C Wheelernull nullPublished in: The New England journal of medicine (2020)
Among patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo. (Funded by AstraZeneca; DAPA-CKD ClinicalTrials.gov number, NCT03036150.).